Inventor · disambiguated record
Mohammad R. Masjedizadeh
Also filed as: MASJEDIZADEH MOHAMMAD · MASJEDIZADEH MOHAMMAD R · MASJEDIZADEH MOHAMMAD REZA
13 granted patents·9 pending applications·34 citations·filing 2015–2025
89Inventor score
Top patents by PatentIndex Score
22 records- 0196US11369613B2Salts and solid form of a BTK inhibitorPRINCIPIA BIOPHARMA INC·Filed 2020·Granted Jun 28, 2022·3 cites·3 claims
- 0295US10456403B2Salts and solid form of a BTK inhibitorPRINCIPIA BIOPHARMA INC·Filed 2018·Granted Oct 29, 2019·9 cites·17 claims
- 0395US10092569B2Salts and solid form of a BTK inhibitorPRINCIPIA BIOPHARMA INC·Filed 2015·Granted Oct 9, 2018·13 cites·10 claims
- 0492US10828307B2Salts and solid form of a BTK inhibitorPRINCIPIA BIOPHARMA INC·Filed 2019·Granted Nov 10, 2020·3 cites·4 claims
- 0587US10899760B2Processes for preparing an FGFR inhibitorPRINCIPIA BIOPHARMA INC·Filed 2020·Granted Jan 26, 2021·2 cites·12 claims
- 0685US11939361B2Compositions of peptide inhibitors of Interleukin-23 receptorJANSSEN PHARMACEUTICA NV·Filed 2021·Granted Mar 26, 2024·2 cites·16 claims
- 0784US10538518B2Processes for preparing an FGFR inhibitorPRINCIPIA BIOPHARMA INC·Filed 2016·Granted Jan 21, 2020·2 cites·7 claims
- 0881US12336999B2Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d] pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl) piperazin-1-yl]pent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2023·Granted Jun 24, 2025·0 cites·20 claims
- 0981US2022370459A1Salts and Solid Form of a BTK InhibitorPRINCIPIA BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 1079US2024309000A1Process for Preparing an FGFR InhibitorPRINCIPIA BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 1176US2025381193A1Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D] Pyrimidin-1-yl]Piperidine-1-Carbonyl]-4-Methyl -4-[4-(Oxetan-3-yl)Piperazin-1-yl]Pent-2-EnenitrilePRINCIPIA BIOPHARMA INC·Filed 2025·Application pending·0 cites
- 1274US12281110B2Processes for preparing an FGFR inhibitorPRINCIPIA BIOPHARMA INC·Filed 2021·Granted Apr 22, 2025·0 cites·19 claims
- 1373US12281120B2Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2023·Granted Apr 22, 2025·0 cites·8 claims
- 1470US2023399330A1Solid Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-d]Pyrimidin-1-YL] Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-EnenitrilePRINCIPIA BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1569US11667641B2Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2021·Granted Jun 6, 2023·0 cites·6 claims
- 1668US11872229B2Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2020·Granted Jan 16, 2024·0 cites·18 claims
- 1767US11708370B2Solid forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2020·Granted Jul 25, 2023·0 cites·16 claims
- 1864US2024254180A1Compositions of peptide inhibitors of interleukin-23 receptorJANSSEN PHARMACEUTICA NV·Filed 2024·Application pending·0 cites
- 1954US2019231784A1Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2017·Application pending·0 cites
- 2051US2022185846A1Methods for synthesizing beta-homoamino acidsPROTAGONIST THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2136US2018193274A1Compositions for ileo-jejunal drug deliveryPRINCIPIA BIOPHARMA INC·Filed 2015·Application pending·0 cites
- 2231US2018015088A1Site specific dosing of a btk inhibitorPRINCIPIA BIOPHARMA INC·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →